Senexis is a growing, small-molecule drug development company that is committed to revolutionising the treatment of diseases resulting from the inevitable process of ageing. Senexis is advancing a pipeline of novel treatments for diseases resulting from the toxicity of amyloid-like proteins. Our pipeline is currently focused on discovering therapies for the treatment of Alzheimer's disease.
There is no investment information
No recent news or press coverage available for Senexis Limited.
We care about your data, and we'd love to use cookies make your experience better.
